We believe that the diagnostic performance of 1H-MRS in the identification of IDH mutational status in gliomas can be further improved by using an integrated approach of analyzing metabolite levels of 2HG, NAA, and Glx together in future studies. The gene discussed is IDH2; the disease is central nervous system cancer.